Converting Insulin-like Growth Factors 1 and 2 into High-Affinity Ligands for Insulin Receptor Isoform A by the Introduction of an Evolutionarily Divergent Mutation
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
MR/K000179/1
Medical Research Council - United Kingdom
MR/R009066/1
Medical Research Council - United Kingdom
- MeSH
- Phosphorylation MeSH
- Insulin-Like Growth Factor I chemistry genetics MeSH
- Insulin-Like Growth Factor II chemistry genetics MeSH
- Insulin chemistry metabolism MeSH
- Humans MeSH
- Ligands MeSH
- Evolution, Molecular MeSH
- Mutation MeSH
- Protein Isoforms MeSH
- Receptor, IGF Type 1 MeSH
- Receptor, Insulin chemistry metabolism MeSH
- Receptors, Somatomedin chemistry genetics MeSH
- Signal Transduction MeSH
- Protein Binding MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- IGF1R protein, human MeSH Browser
- IGF2 protein, human MeSH Browser
- Insulin-Like Growth Factor I MeSH
- Insulin-Like Growth Factor II MeSH
- Insulin MeSH
- Ligands MeSH
- Protein Isoforms MeSH
- Receptor, IGF Type 1 MeSH
- Receptor, Insulin MeSH
- Receptors, Somatomedin MeSH
Insulin-like growth factors 1 and 2 (IGF-1 and -2, respectively) are protein hormones involved not only in normal growth and development but also in life span regulation and cancer. They exert their functions mainly through the IGF-1R or by binding to isoform A of the insulin receptor (IR-A). The development of IGF-1 and IGF-2 antagonists is of great clinical interest. Mutations of A4 and A8 sites of human insulin lead to disproportionate effects on hormone IR binding and activation. Here, we systematically modified IGF-1 sites 45, 46, and 49 and IGF-2 sites 45 and 48, which correspond, or are close, to insulin sites A4 and A8. The IGF-1R and IR-A binding and autophosphorylation potencies of these analogues were characterized. They retained the main IGF-1R-related properties, but the hormones with His49 in IGF-1 and His48 in IGF-2 showed significantly higher affinities for IR-A and for IR-B, being the strongest IGF-1- and IGF-2-like binders of these receptors ever reported. All analogues activated IR-A and IGF-1R without major discrepancies in their binding affinities. This study revealed that IR-A and IGF-1R contain specific sites, likely parts of their so-called sites 2', which can interact differently with specifically modified IGF analogues. Moreover, a clear importance of IGF-2 site 44 for effective hormone folding was also observed. These findings may facilitate novel and rational engineering of new hormone analogues for IR-A and IGF-1R studies and for potential medical applications.
References provided by Crossref.org
A radioligand binding assay for the insulin-like growth factor 2 receptor